Inclusion Criteria:  Patients with age between 18 to 75 years; Patients'gender was not limited; Patients with locally advanced cholangiocarcinoma who have a clear diagnosis of the primary disease and require surgical resection or potential surgical resection; No history of radiotherapy and chemotherapy; Willing to accept this clinical trial, sign informed consent and be able to cooperate with follow-up.  Exclusion Criteria:  Women during pregnancy or breastfeeding, and those with mental illness; Patients allergic to porphyrin drugs, porphyria; Long-term use of glucocorticoids or autoimmune suppression; Surgical contraindication, including:  Child-Pugh C with hepatic encephalopathy Anyone with heart, lung, kidney dysfunction or other organ dysfunction, and cannot tolerate surgery.Hepatic ducts stone disease, who was diagnosed as Acute Cholangitis of Severe Type, especially complicated with bacteremia or septic shock. End stage disease, complicated with biliary cirrhosis or portal hypertension.Patients with long- term obstructive jaundice, dehydration, electrolyte disturbance or coagulation defects; Patients have the tendency or history of bleeding.